PR83177

SAN DIEGO and TOKYO and WETTEREN, Belgium, Mar. 10, 2020 /PRNewswire=KYODO JBN/--

Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of

biopharmaceutical contract development and manufacturing services, announced

today the formation of its External Advisory Board (EAB) to provide insight

into industry trends and high-level advice to the Company's leadership team.

Logo - https://mma.prnewswire.com/media/751177/Aji_BioPharma_Logo.jpg

"We are honored to have attracted such a diverse team of bio-pharmaceutical

manufacturing industry leaders to our External Advisory Board," said David Enloe,

President and CEO of Aji Bio-Pharma. "The deep expertise and experience of our EAB

will be invaluable as we continue to grow our company in order to become a more

well-rounded partner to our clients. The formation of this Board represents a significant

step along our path to achieving our Vision Statement of being a leading, trusted,

and innovative partner to our customers and to our employees."

The expert members of the External Advisory Board include:

Dr. Magda Marquet is the co-founder and co-CEO of ALMA Life Sciences, LLC, an

early stage investment firm creating and growing innovative healthcare companies.

Prior to starting ALMA Life Sciences, Dr. Marquet co-founded Althea Technologies,

where she led the company to become a highly profitable contract manufacturing

organization, ultimately resulting in a successful sale of Althea to Ajinomoto.

She also co-founded AltheaDx, a commercial stage precision medicine company

with the world's leading pharmacogenomics test for anxiety and depression.

Dr. Marquet held several positions in product development and pharmaceutical

development in companies such as Vical and Amylin Pharmaceuticals. Dr. Marquet

holds a Ph.D in Biochemical Engineering from INSA/University of Toulouse, France.

Jim Miller is an advisor on manufacturing strategy and a pre-eminent authority

on the biopharmaceutical contract manufacturing and development industry.

He is the founder and former President of PharmSource, the industry's principal

source of market intelligence. He has advised most major CMOs on business

strategy, major capital investment decisions and acquisitions; and has served

on due diligence teams for high profile acquisitions made by private equity

firms. Jim was also a consultant in corporate strategy at the Boston Consulting

Group and an economist at The World Bank. He holds an MBA from the Stanford

University Graduate School of Business.

Bob Kanuga is an experienced pharmaceutical leader with a demonstrated history

in vaccine and biotechnology manufacturing, global procurement, contract

manufacturing, licensing, mergers & acquisitions, and strategy development.

He recently held the position of Vice President, Global Supply Business Development,

while working at Merck & Co., Inc. for 30 years. Bob is well-known  within industry as

a strong commercial and manufacturing professional with a MBA focused in Marketing

and BS in Industrial Engineering from Lehigh University.

Joseph Colleluori is a veteran pharmaceutical and chemical industry executive.

In 2003, Joe joined Lonza Inc. where he successfully combined the activity and

business of the small molecule and biopharmaceuticals commercial organization

which is now the foundation of Lonza Pharma & Biotech. He then went on to serve

as Senior Vice President responsible for Corporate Strategy, Mergers & Acquisition

and Risk Management and was a member of the Capital Investment Committee.

He recently held the role of Head of Biopharma Sales and Business Development

for the EMEA region. In his more than thirty years in the industry, Joe has completed

more than thirty acquisitions and divestitures in excess of $10 billion. Joe has a bachelor's

degree in Organic Chemistry from Bard College in New York; an M.S. in Organic Chemistry

from the University of New Hampshire and Executive Business Training at New York

University and the Wharton School of the University of Pennsylvania.

About Ajinomoto Bio-Pharma Services

Ajinomoto Bio-Pharma Services is a fully integrated contract development and

manufacturing organization with sites in Belgium, United States, Japan, and

India, providing comprehensive development, cGMP manufacturing, and aseptic

fill finish services for small and large molecule APIs and intermediates.

Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and

capabilities for pre-clinical and pilot programs to commercial quantities,

including Corynex(R) protein expression technology, oligonucleotide synthesis,

antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis,

continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is

dedicated to providing a high level of quality and service to meet our client's

needs. Learn more: www.AjiBio-Pharma.com

SOURCE: Ajinomoto Bio-Pharma Services

CONTACT: Natalie Kuczkowski

Natalie.Kuczkowski@US.AjiBio-Pharma.com

+1-858-281-7386